OPPORTUNITIES IN DIABETES

Context:

A Big Pharma company with no activity in diabetes is interested in entering this market.

Initial inputs:

The company is interested in both types of diabetes and is focused on targeting the US market (2011 estimates according to the American Diabetes Association: 25.8 million adults and children have diabetes in the US – 8.3% of the population. It is assumed that the company has sufficient internal resources and capabilities (production, manufacturing, and marketing) to enter a new market such that these are not limiting factors in this project.

Outcome:

The questions to which the company is asking answers are summarized in the suggested chapters of the report:

- 1. Biology/general mechanism and druggable targets
- 2. Types of diabetes → estimate the market potential. Which type is the most attractive one?
- 3. Current drugs for each type of diabetes → action mechanism, price, revenues generated
- 4. Current tests/tools for diagnostics → technology, price, revenues generated
- 5. Companies involved → which ones are best positioned in this market? What is the competitive environment?
- 6. Final recommendations

15.136J / 7.547J / 10.547J / ESD.691J / HST.920J / BCMP 230 Principles and Practice of Drug Development Fall 2013

For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms.